Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
November 13 2008 - 5:00PM
PR Newswire (US)
SAN DIEGO, Nov. 13, 2008 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) will be presenting at the
Lazard Capital Markets Healthcare Conference in New York on
Wednesday, November 19, 2008 at 8:30 a.m. ET. Daniel M. Bradbury,
president and chief executive officer of Amylin Pharmaceuticals,
will be providing a corporate overview. The live presentation will
be Web cast, and a recording will be made available following the
event. The Web cast and recording will be accessible through
Amylin's corporate Web site, located at http://www.amylin.com/. To
access the live Web cast, please log on to Amylin's site
approximately fifteen minutes prior to the presentation to register
and download any necessary audio software. About Amylin
Pharmaceuticals Amylin Pharmaceuticals is a biopharmaceutical
company committed to improving lives through the discovery,
development and commercialization of innovative medicines. Amylin
has developed and gained approval for two first-in-class medicines
for diabetes, SYMLIN(R) (pramlintide acetate) injection and
BYETTA(R) (exenatide) injection. Amylin's research and development
activities leverage the Company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin
is headquartered in San Diego, California. Further information on
Amylin Pharmaceuticals is available at http://www.amylin.com/.
DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Michael York,
Senior Director, Investor Relations of Amylin Pharmaceuticals,
Inc., +1-858-552-2200, ext. 8602 Web Site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024